Evidence map›Paper›PMID 22466801›Full record

ArticleHuman molecular genetics2012

Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone.

Zhengyu Cao, Susan Hulsizer, Flora Tassone, Hiu-tung Tang, Randi J Hagerman, Michael A Rogawski, Paul J Hagerman, Isaac N Pessah

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 97 citations in OpenAlex.

  1. Trial
  2. Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017
    Trial
  3. Trial
  4. Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): a double-blind brain potential study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Gene×environment interactions in autism spectrum disorders.Current topics in developmental biology · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zhengyu CaoDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California-Davis, CA 95616, USA.
Susan Hulsizer
Flora Tassone
Hiu-tung Tang
Randi J Hagerman
Michael A Rogawski
Paul J Hagerman
Isaac N Pessah
University of California, Davis · US

Funding

Characterization and Treatment of CNS Abnormalities in Premutation Carriers (4 ofRL1AG032115 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, RANDI J. · 2007 to 2011
$5.8M
Development of targeted therapeutic agents for the treatment of FXTAS (2 of 6)RL1AG032119 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2007 to 2011
$4.1M
Neuro Therapeutics Research Institute (1 of 6)UL1DE019583 · NIDCR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2008 to 2011
$3.0M
Human iPSC neuronal models for early and late phases of FXTAS neurodegenerationRC1AG036022 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2009 to 2010
$787k
Identification of novel therapeutic approaches for TETS and OP intoxicationR21NS072094 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEIN, PAMELA J, ROGAWSKI, MICHAEL A. · 2010 to 2011
$767k
NIA NIH HHS RC1 AG036022NIA NIH HHS RL1 AG032115NIA NIH HHS RL1 AG032119NIDCR NIH HHS UL1 DE019583NIEHS NIH HHS R01 ES011269NINDS NIH HHS R21 NS072094
6 · The paper itself

Abstract

Premutation CGG repeat expansions (55-200 CGG repeats; preCGG) within the fragile X mental retardation 1 (FMR1) gene cause fragile X-associated tremor/ataxia syndrome (FXTAS). Defects in neuronal morphology and migration have been described in a preCGG mouse model. Mouse preCGG hippocampal neurons (170 CGG repeats) grown in vitro develop abnormal networks of clustered burst (CB) firing, as assessed by multielectrode array recordings and clustered patterns of spontaneous Ca(2+) oscillations, neither typical of wild-type (WT) neurons. PreCGG neurons have reduced expression of vesicular GABA and glutamate (Glu) transporters (VGAT and VGLUT1, respectively), and preCGG hippocampal astrocytes display a rightward shift on Glu uptake kinetics, compared with WT. These alterations in preCGG astrocytes and neurons are associated with 4- to 8-fold elevated Fmr1 mRNA and occur despite consistent expression of fragile X mental retardation protein levels at ∼50% of WT levels. Abnormal patterns of activity observed in preCGG neurons are pharmacologically mimicked in WT neurons by addition of Glu or the mGluR1/5 agonist, dihydroxyphenylglycine, to the medium, or by inhibition of astrocytic Glu uptake with dl-threo-β-benzyloxyaspartic acid, but not by the ionotropic Glu receptor agonists, α-2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid or N-methyl-d-aspartic acid. The mGluR1 (7-(hydroxyimino)cyclopropa [b]chromen-1a-carboxylate ethyl ester) or mGluR5 (2-methyl-6-(phenylethynyl)pyridine hydrochloride) antagonists reversed CB firing. Importantly, the acute addition of the neurosteroid allopregnanolone mitigated functional impairments observed in preCGG neurons in a reversible manner. These results demonstrate abnormal mGluR1/5 signaling in preCGG neurons, which is ameliorated by mGluR1/5 antagonists or augmentation of GABA(A) receptor signaling, and identify allopregnanolone as a candidate therapeutic lead.

Indexed as

Amino Acid Transport System X-AGAnimalsAspartic AcidAstrocytesCells, CulturedExcitatory Amino Acid AntagonistsFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeGABA Plasma Membrane Transport ProteinsGene Knock-In TechniquesHippocampusMaleMiceMice, Inbred C57BLMice, KnockoutNeuronsAmino Acid Transport System X-AGAspartic AcidbenzyloxyaspartateExcitatory Amino Acid AntagonistsFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1GABA Plasma Membrane Transport ProteinsGrm5 protein, mousemetabotropic glutamate receptor type 1N-MethylaspartatePregnanoloneReceptor, Metabotropic Glutamate 5Receptors, GlutamateReceptors, Metabotropic GlutamateRNA, Messenger

Identifiers

PMID22466801
PMCPMC3373240
OpenAlexW2143798904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.